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Abstract 
This thesis studies the potential for using molecular testing for ESBL in Norwegian hospitals. 
Background material was obtained by checking the prices of existing kits, doing an interview 
with one of Norway’s foremost experts on ESBL testing and performing calculations based 
on public statistics. 
A survey was then performed that was expected to form the basis of a price sensitivity analysis. 
The number of respondents was too low for statistical analysis, but a very rough estimate for 
the kit prices that microbiological hospital labs are willing to pay was obtained. The realism 
of this price level is discussed. 
All responses were from medium sized hospitals. They also stated that the throughput they 
needed would be 8 to 24 samples per run. This confirms theoretical estimates of the throughput 
needed for Norwegian hospitals of medium size. 
 
Keywords: ESBL detection; Price sensitivity; Prices of kits and instruments  
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1. Introduction 
1.1 ß-lactam antibiotics 
These are a class of antibiotics which contains all those antibiotics agents whose molecular 
structure carry beta lactam and this is essential for the function of all the antibiotics in this 
group. The beta-lactam ring is shown in figure 1. This class of antibiotics have 3-carbon and 
1-nitrogen in their molecular structure which is highly reactive. This antibiotic inhibit the 
formation of bacterial cell wall, by interfering with the protein necessary for cell wall 
formation where later bacteria get either killed or growth inhibition. Some bacterial enzymes 
named as penicillin binding protein (PBP) have major role in peptidoglycan synthesis and 
these antibiotics bind to these PBP which later leads to lysis and cell death (Etebu & Arikekpar, 
2016).  
 
Figure 1: Structure of Beta-lactam ring (Etebu & Arikekpar, 2016). 
The ß-lactam antibiotics are mainly classified into four groups namely: Penicillins, 
Cephalosporins, Monobactams and Carbapenems. The frequency of their use in the USA is 
shown in the table 1. 
 
Table 1: The use of different ß-lactam antibiotics in the USA in the decade from 2004 to 2014 
(Bush & Bradford, 2016). 
Class of ß-lactam Percentage of prescriptions 
Narrow spectrum penicillins 3.12 
Broad spectrum penicillins 36.54 
Cephalosporins 47.49 
Monobactams 1.66 
Carbapenems 11.20 
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Table 1 reflects the fact that penicillins and cephalosporins are general purpose antibiotics 
whereas carbapenems are antibiotics of last resort. Only one monobactam is in common use, 
and it share of the market is marginal (Arne Deggerdal, personal communication). 
1.1.1 Penicillins 
This class contains beta lactam compounds where 6-aminopenipenicillanic acid ring are 
centred and other rings are in side chains, as is shown in the figure 2, part 1 (Etebu & 
Arikekpar, 2016). The penicillin get their potency from 6-aminopenipenicillanic acid nucleus 
and mainly work against gram positive bacteria (Berendsen et al., 2013).  
1.1.2 Cephalosporins 
This class is similar to penicillin both in structure and function. It contains 7-
aminocephalosporanic acid in the nucleus and 3,6-dihydro-2 H-1,3 thiazane rings. The general 
structure of cephalosporins is shown in figure 2, part 2. There has been developed several 
generations of cephalosporins, which is mentioned in table 2. Their latest generations are more 
effective against gram negative bacteria (Pegler & Healy, 2007). This is summarized in table 
3. 
 
Figure 2: Structure of Penicillin (top) and cephalosporin (bottom), red color indicates the 
beta lactam ring (Etebu & Arikekpar, 2016). 
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Table 2: Cephalosporin family (TulaneUniversity, 2016).  
Category Parental agents Oral agents 
First generation Cefazolin Cephalexin 
Second generation Cefotetan, Cefoxitin, 
Cefuroxime 
Cefuroxime axetil, Cefaclor  
Third generation Cefotaxime, Ceftazidime, 
Ceftriaxone 
Cefixime, Cefdinir 
Fourth generation Cefepime  
Fifth generation Ceftaroline  
 
Table 3: Generational coverage (TulaneUniversity, 2016). 
Generation Gram Negatives Gram Positives ß-Lactamase 
Stability 
1st + + + + +/- 
2nd + + + + + 
3rd + + + + + + 
4th + + + + + + + + 
5th + + + + + + + + + 
 
1.1.3 Monobactams 
These antibiotics are part of beta lactam compounds but are different from other beta lactams, 
in monobactams beta lactam ring remain in one side and is not attached to any other ring. 
Aztreonam is a monobactam that is commercially available having narrow spectrum activity 
and act mostly against gram negative pathogens (Etebu & Arikekpar, 2016). The structure of 
Aztreonam is shown in figure 3. 
 
Figure 3: Structure of the Monobactam Aztreonam (Etebu & Arikekpar, 2016). 
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1.1.4 Carbapenems 
Carbapenems have the property of wide spectrum antibiotic which gives potency to this 
antibiotic to fight against ESBL and Metallo beta lactamase. Because of this reason this 
antibiotic is considered to be trustworthy and with rise in resistant to this antimicrobial agent 
is considered to be main people health related problems. Due to its wide spectrum property, it 
gives detrimental effect to all Gram-positive bacteria and gram-negative bacteria as well as 
anaerobic bacteria (Codjoe & Donkor, 2017). The general structure of carbapenems is shown 
in figure 4. 
 
Figure 4: Structure of Carbapenem (Etebu & Arikekpar, 2016). 
1.2 Extended Spectrum ß-lactamases (ESBL) 
ß-lactamases are enzymes that hydrolyze the ß-lactam ring and it can be chromosomal or 
plasmid borne. The plasmid borne enzymes can be transferred from one bacterial species to 
another (Bush & Bradford, 2016). ESBL are ß-lactamases that will hydrolyze ß-lactam 
compounds which will not normally be broken down by ß-lactamases, and are plasmid borne. 
When one talks about ESBL the subject is an enzyme carried on a plasmid, not an organism. 
Bacteria most likely to harbour the ESBL plasmids are members of the Enterobacteriaceae 
family, for instance E.coli or Klebsiella pneumoniae (Wintermans et al., 2013). There are 
several classes of ESBL among which some of them are mentioned below. 
1.2.1 Temoniera (TEM) 
TEM-1 is most easily experienced beta-lactamase in Gram-negative microbes and because of 
this production the resistance against ampicillin and ampicillin is increased up to 90% 
(Cooksey et al., 1990). The change in the position of amino acid around the active site of the 
enzyme is responsible for change in its configuration which gives entry to oxyimino beta 
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lactam substances. Because of these changes in amino acid positions 140 types of TEM have 
been described (Bradford, 2001; Jacoby & Munoz-Price, 2005).  
1.2.2 Sulfhydrylvariable (SHV) 
The enzyme SHV become prominent in Enterobacteriaceae in last decade of 20th century but 
now found in different epidemiological condition of human, animal and environment. SHV 
have evolved from narrow to extended-spectrum of hydrolysis, due to change in the amino 
acid which alter the position at the active site of beta-lactamases (Liakopoulos, Mevius, & 
Ceccarelli, 2016). Till now because of this substitution mechanism 50 Types of SHV have 
been recognized (Jacoby & Munoz-Price, 2005). 
1.2.3 Cefotaxime-munich (CTX-M) 
Those common ESBL which do not come into TEM and SHV family is categorized in to this 
to focus the greater effect against cefotaxime than to ceftazidime. There are nearly 40 CTX-
M have been recognized and some of them more easily hydrolyze the ceftazidime than 
cefotaxime. The more commonly found are CTX-M-14, CTX-M-3 and CTX-M-2 (Bradford, 
2001; Jacoby & Munoz-Price, 2005).  
1.2.4 OXA 
This group of enzyme is characterized by hydrolysing activity against oxacillin and cloxacillin 
and on this basis it has been named as OXA. This group of enzyme also gives resistance to 
ampicillin and cephalothin. There is very little similarity among the members of this group 
enzymes (Bradford, 2001).  
1.2.5 Carbapenemases 
Carbapenemases belong to a diverse group of ß-lactamases that can break down carbapenems. 
This is a serious problem since carbapenems are antibiotics of last resort (Komatsu et al., 
2018). Carbapenemases can be serine ß-lactamases (class A or D) or metallo ß-lactameases 
(class B) (Queenan & Bush, 2007).  
New ESBLs are detected at regular intervals, but that it takes time before they become 
clinically relevant. Carbapenemases are not considered ESBLs, but this is more a matter of 
definition than a real difference. Anyway, they both pose the same type of problem. An 
example is OXA-48, which sometimes has carbapenemase activity (Arne Deggerdal, personal 
communication). 
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1.3 Clinical Significance of ESBL  
Most of the bacteria carrying ESBL are not necessarily pathogens.  There are two aspects of 
the clinical significance of ESBL. 
1. To prevent the spread of bacteria carrying the plasmid between patients or between 
patients and staff, even when the bacteria carrying the plasmid do not cause disease. 
To safeguard against this, the hospitals perform screening of patients, relatives and 
staff that may have been in contact with such bacteria. Samples for this is referred to 
as screening samples. Bacteria negative for ESBL are not picked up in screening. 
2. If a patient has a disease caused by a bacterium that carries ESBL, this has implication 
for the treatment as well as for the prognosis. Samples from these patients are referred 
to as clinical samples. From these tests the hospital will know how frequent ESBL is 
in the population of bacteria that causes the specific disease in the patient, since they 
already have registered infection with that type of bacteria before they test for the 
presence of ESBL. 
In the Scandinavian countries the routines are as follows: 
If ESBL is indicated in a screening, steps are taken to avoid spread. If a patient and the presence 
of ESBL is not related to his disease, he will be isolated, treated for his disease in the normal 
way, but nothing will be done about the ESBL. If it is relatives or staff, their access to the 
hospital will be restricted, but nothing will be done about the ESBL status. Over time the ESBL 
status will spontaneously change to negative (Arne Deggerdal, personal communication). 
If ESBL is indicated in bacteria causing the disease of a patient, the patient will be isolated 
and the treatment will be modified to use antibiotics that are not inactivated by the ESBL. 
Usually this involves the use of carbapenems, but if the ESBL is a carbapenemase it is more 
complicated (Lingaas, 2016).  
  
 15 
Table 4: The cost per day of the stay at hospitals without treatment (Helsedirektoratet, 2019). 
Year Price (NOK) 
2019 4,885 
2018 4,747 
2017 4,622 
2016 4,505 
2015 4,387 
2014 4,255 
 
The additional cost per day of keeping a patient in contact isolation (keeping the patient 
shielded from fellow patients) was between NOK 4953 and NOK 6532 in 2014 according to 
a lecture given by Petter Elstrøm, from Folkehelseinstituttet (The Norwegian Institute of 
Public Health) (Elstrøm, 2016).  
1.4 Testing for ESBL 
Norwegian hospitals in general follow NordiCAST and EUCAST rules (Parajuli, 2018). 
According to EUCAST, the recommended strategy for the detection of ESBLs in 
Enterobacteriaceae is based on non-susceptibility to indicator oxyimino-cephalosporins, 
followed by phenotypic (and in some cases genotypic) confirmation tests. The recommended 
methods for ESBL screening in group 1 Enterobacteriaceae are broth dilution, agar dilution or 
disk diffusion. It is necessary that both cefotaxime (or ceftriaxone) and ceftazidime are used 
as indicator cephalosporins, as there can be large differences in Minimum Inhibitory 
Concentrations (MICs) of cefotaxime (or ceftriaxone) and ceftazidime for different ESBL 
producing isolates. After screening, ESBL confirmation is done by different phenotypic test 
(EUCAST, 2013).  
The NordiCAST rules generally recommend using the tests described by EUCAST, but also 
opens up for PCR based tests and in all cases will be PCR reactions with primers against the 
ESBL gene. Depending of the test setup this can theoretically be a set of reactions against 
different ESBLs or a multiplex PCR detecting several ESBLs in one reaction. Tests can either 
be in-house, meaning that the hospital has designed primer sets and/or probes and then bought 
a general purpose PCR kit (everything except primers/probes) or it can be a commercial ESBL 
kit, meaning that the manufacturer has designed primer sets, probes (if they are used) and 
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supply them with the general PCR components. This also means that the kit has been IVD CE 
approved. In practical use there is no difference between the two types of PCR based kits 
(Arne Deggerdal, personal communication).  
There are two large weaknesses of the PCR based methods as well as two important strengths. 
The weaknesses are: 
• Only ESBLs that have been previously described can be detected. According to a 
survey carried out in 2018, some of the largest hospitals in Norway do not consider 
this a problem (Parajuli, 2018). 
• It is difficult to find commercial kits that will even detect all of the well known ESBL 
variants (Parajuli, 2018).  
The strengths are: 
• The time to results is short, only a matter of a couple of hours, as low as 90 minutes in 
some cases (Parajuli, 2018). 
• There are cases where ESBLs are inducible and the process is too slow for the strain 
to show up as resistant in a traditional phenotypic test. Then the molecular test will be 
correct and the traditional one will be a false negative (Rawat & Nair, 2010).  
 
Other types of tests for ESBL 
Sequencing: One of the molecular diagnostic method is amplicon based Next Generation 
Sequencing (NGS) and has been used in Hospital Acquired Infection Bio Detection system, 
which is used to detect the pathogenic organisms and the genes which is resistant to 
antimicrobial agents. This bio detection system removes the negative samples and detect the 
positive sample directly from the raw material and helps in the easy and fast detection process 
(Peker et al., 2018).  
 
MALDI-TOF: The molecular detection technique like Matrix Assisted Laser Desorption 
Ionization time of flight Mass Spectrometry (MALDI-TOF MS), detects the genes which are 
responsible for ESBL activity and its limiting factor is that it cannot detect all of the ESBL 
encoding gene and is expensive. A kit named Rapid ESBL Screen kit 98022 is commercially 
available and gives the result within 2 hours but have some limitations too (Poirel, Fernandez, 
& Nordmann, 2016).  
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Loop Mediated Isothermal Amplification (LAMP): This method amplifies the DNA in fast 
pace with high specificity and efficiency under isothermal conditions. In addition, along with 
reverse transcription, it can amplify RNA sequences with greater efficiency (Notomi et al., 
2000). The principle of LAMP is shown in figure 5.  
 
Figure 5: The LAMP process (Dhama et al., 2014). 
 
1.4.1 Commercial ESBL detection kits 
eazyplex® SuperBug 
The principal of LAMP was described above. On the basis of this principle a device named 
Genie II has been designed which uses a set of kits named eazyplex® SuperBug from Amplex 
Diagnostics GmbH, for the detection of pathogens as mentioned in the report of NICE-2017 
(NICE stands for National Institute for Health and Care Excellence), the time duration for 
complete result is 30 minutes (NICE, 2017).  
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Gene Proof ESBL PCR Kit 
The ESBL PCR kit is designed by GeneProof biotechnological company. This kit is especially 
designed for the detection of bla SHV  and bla CTX-M  genes by RT-PCR (Real Time- Polymerase 
Chain reaction) method. The kit has been internally standardised which is included in the 
reaction mixture that enables the identification of all the five known variants of CTX-M (CTX-
M 1, CTX-M 2, CTX-M 8, CTX-M 9 and CTX-M 25). The kit takes the advantage of hot-
start technology which reduces the non-specific reactions. The Specificity is 100% and 
Sensitivity is 95%  for both CTX-M and SHV (GeneProof, 2016).  
Allplex™ Entero-DR Assay 
Allplex™ Entero-DR Assay is a multiplex real time PCR assay which can detect and identify 
8 antibiotic resistant genes simultaneously. Its’ important aspect is it can monitor three major 
resistance of antibiotics namely carbapenem, vancomycin and extended spectrum of beta 
lactam in a single reaction within 3 hours. It uses rectal swab or bacterial colony for sample 
(Seegene, 2019).  
1.5 Spread of ESBL 
The first time ESBL was reported was in 1983 and plasmid borne AmpC beta-lactamases was 
reported in 1988. Usually, ESBLs are a mutant form, plasmid borne beta-lactamases originated 
from older beta-lactamases (such as TEM-1, TEM-2, SHV), which have an extended substrate 
profile which hydrolyse the all cephalosporins, penicillins and  aztreonam (Thomson, 2001).  
ESBLs when reported in 1983, it was described in Enterobacteriaceae and Pseudomonadaceae 
in different parts of world mainly in Klebsiella pneumoniae and Escherichia coli. The majority 
of ESBLs found in clinical sample are TEM and SHV types which have evolved from narrow 
spectrum beta-lactamases like TEM-1, TEM-2 and SHV-1. The CTX-M enzyme have 
originated from Kluyvera spp.,being noticed in Enterobacteriaceae and reported from Asia, 
Africa, Europe, South America and North America (Pitout, Nordmann, Laupland, & Poirel, 
2005).  
During 80s and 90s, the ESBL producers were mainly found in Hospital environment and 
mainly in ICU (Intensive care Unit), and the responsible hosts for this enzyme production were 
Klebsiella and Enterobacter spp. In one of the surveys it is found that the percentage of E. coli 
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associated with ESBL production is rising and is 3.6% in 2005 rises to 4.8% in 2008. This 
number is mainly found in USA, Canada or Israel but it is less in Europe (Schoevaerdts et al., 
2011).  
With the passes of time hospital acquired infections is rising and is becoming top ranked 
problem on the globe and the responsible pathogen is Klebsiella spp., which produces ESBLs. 
This is the main concern because of few numbers of antibiotic for its treatment and also its 
transmission rate is fast to other Gram-negative bacilli or Enterobacter (Bellíssimo-Rodrigues 
et al., 2006).  
Until the nineties, there were two types of ESBL active globally, namely Temoniera (TEM) 
and Sulfhydrylvariable (SHV) types associated mainly with hospital outbreaks and the 
bacteria which produced this enzyme was predominantly Klebsiella pneumoniae. But after 
2000 there erupted another type of ESBL enzymes called Cefotaxime-munich (CTX-M) and 
the bacteria responsible for this enzyme was mainly Escherichia coli. Also, some of the study 
was done in the clinical samples of the hospital and they found that other than E. coli, K. 
oxytoca and K. pneumoniae also have the capacity to produce CTX-M enzyme and mostly 
because of gram negative bacteria, resistance has been occurred. So one of the mode of 
transmission of ESBL to human is either by physical contact or taking of contaminated food 
infected with ESBL producing strains. The food which is of animal origin have higher chances 
of accumulating ESBL and the wide spectrum antibiotic Cephalosporin inactivated because of 
enzymes produced by these bacteria (Vásquez-Jaramillo, Ramírez, Akineden, & Fernández-
Silva, 2017).  
In 2011, WHO (World Health Organization), has a statement where it is mentioned that 
Healthcare Related Infections are more in low and middle income countries and it is 10.1% 
where as its number is less in high income country and is 7.6%. When the number of staying 
days in hospital is more, it is directly linked to more antibiotic resistant, more chance of 
increased Health Related Infections (HRI) (Hendrik, Voor In 't Holt, & Vos, 2015).  
1.6 MRSA For cost comparison  
Methicillin resistant Staphylococcus aureus (MRSA) is pathogen which is resistant to many 
drugs and its infection is related to hospital acquired, length of stay in the hospital may be 
longer and may leads to mortality. As mentioned earlier patient infected with this pathogen 
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also have to be kept in contact isolation and the cost is also extra like for nursing time, 
protective materials, cleaning stuff, hygienic things and so on (Hubner et al., 2014).  
It is seen that MRSA screening itself is expensive and if the patient has to stay for longer then 
it is another increase in expenses. In order to reduce the cost burden, quick detection test has 
to be implemented. And factor which increases the cost burden are longer stay in hospital, cost 
from microbiological analysis of the swab, cost from the disposable items, clothing, nursing 
time , laundry, and cost related to contact isolation and so on (Goldsack et al., 2014).  
The fast and accurate detection of the pathogen which carry MRSA genes help in reduction of 
hospital infection and unwanted contact isolations as well as costs associated to it. When the 
sample (swabs from nose, groin, axilla, wounds) is collected, it should go through the PCR 
method which is one of the genotypic methods to detect the Staphylococcus which is resistant 
to methicillin. Though the traditional culture method can also be used to identify the pathogen 
but this culture technique some time give the false positive result and creates further problems 
in treatment mechanisms. On the other hand, PCR method give accurate result and also the 
method is fast in detection and hence reduces the costs, which also states that genotypic 
method is necessary before the culture technique (Andrea Tübbicke, 2013; Gidengil et al., 
2015; McKinnell et al., 2015).  
Though the number of MRSA cases is rising globally, its rate is still low in Scandinavian 
countries, which is due to strict control measures. In Norway, the proportion of S. aureus 
isolates which are resistant to methicillin has been less than 1% for nearly 10 years but the 
reported occurrence rate of MRSA in general population has raised from 0.5 per 100,000 
populations per year in 1995 to 19 per 100,000 population per year in 2010 (Li, Ulvin, Biboh, 
& Kristiansen, 2012). 
Norwegian guidelines for MRSA require the following patients to be tested at admittance: 
• Patients who have previously tested positive and have not had at least three negative 
tests after that. 
• Patients who have previously tested positive during the last 12 months. 
• Patients who have been living with someone that are MRSA positive. 
• Patients who have been in contact with someone that are MRSA positive without using 
protective gear. 
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• Patients that during the last 12 months have been admitted to a hospital, been 
extensively treated or examined by health staff or worked in a health institution, 
refugee camp or orphanage outside the Nordic countries. 
New staff are tested according to the same criteria (Arne Deggerdal, personal communication). 
Accute patients are kept in isolation during tests and the traditional culture test take about 48 
hour, which increases extra costs. But the new method based on PCR called Xpert MRSA 
assay which take only 75 minutes to give result. Even though this method is expensive but 
studies suggest PCR based method is more sensitive and more specific (Li et al., 2012). The 
Xpert MRSA PCR method combines the three steps for complete rapid testing, purification of 
sample, amplification of nucleic acid and detection (Andersen et al., 2010).  
Price for MRSA detection kit 
Price is from the site of the distributor Medac Diagnostica GmbH. 
Price for an MRSA detection kit for 25 reactions is 515 EURO and for 50 reactions is 935 
EURO, 
Here, if 1 EURO= 10 NOK (Approximately) 
Then for 50 reactions, price is 935 EURO. 
For 1 reaction 935/50 =18.7 EURO 
Therefore, for 1 reaction price is 18.7*10 = 187 NOK. 
But for 25 reactions price is 515 EURO and for unit reaction 515/25=20.6, which is 206 NOK 
(MedacGmbHDiagnostika, 2017).  
1.7 Price Sensitivity   
Price sensitivity is the degree to which consumers are affected by the change in the price of 
product or services. Price elasticity of demand is a calculated measure for price sensitivity. 
Price sensitivity, when properly calculated, can predict changes in customer purchase behavior 
in response to a certain change in product price. This helps the manufacturer to go for better 
decision in price setting.  
There are several pricing strategies that suppliers of medical tests could possibly use, but the 
two most common are: 
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1. Cost plus pricing. This means that the selling price is the sum of the cost price plus a 
mark-up. The mark-up is basically the profit, cost price is the sum of the COGS and 
the products part of the company’s overhead. Note that if competing products have 
lower cost price, they will with this system also have a selling price advantage. 
2. Competitive pricing is based on the selling price of competing products. It will usually 
mean that a company will have to accept smaller profit margins when a new product 
is introduced. It is a strategy which is usually deemed necessary if the product is price 
sensitive. 
Some products which do not show any reaction on change in price are said to be price inelastic 
and these products are used on daily basis. 
Price elasticity of demand (PEoD) measures the sensitivity of quantity demanded if there is 
change in the price of the product. 
PEoD = (% Change in the Quantity Demanded) / (% Change in the price).  
PEoD is expressed on the following conditions. 
• If PEoD >1, price is elastic and it is sensitive to change the price. 
• If PEoD = 1, Demand is unit elastic. 
• If PEoD < 1, Demand is price inelastic (Fiona, 2016).  
1.8 Aim of the study 
There were mainly two aims for this study namely: 
1. To estimate a price where molecular tests are competitive with traditional techniques. 
2. To perform a price sensitivity analysis. 
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2. Material and Methods 
2.1 Literature survey methods 
The literature search was done online and the databases accessed was Google Scholar, Web 
of Science, Oria (University online library) and Science Direct. In addition information was 
obtained by looking directly in official Norwegian statistics and checking the web-sites of 
relevant hospitals and the Norwegian “Folkehelseinstituttet”. 
2.2 Interview techniques 
The interview with ESBL specialist professor Rafi Ahmad was performed as an open-ended, 
exploratory interview.  
2.3 Questionnaire 
The questionnaire was prepared based on the information from the literature review focusing 
on a price where molecular tests are competitive with traditional techniques. The questionnaire 
was aimed for different hospitals in Norway and it contains 8 questions in total. Among which 
some questions have Yes-No answers, some multiple choice answers and one open ended 
questions where participants can express their views. 
2.4 Survey method 
The electronic questionnaire was sent to different hospitals with microbiology department in 
Norway by e-mail address provided by University. The questionnaire was in fillable PDF 
forms where it can be fill, save and send back by e-mail. The Email addresses of different 
hospital in Norway was obtained from their website tracking through online web pages. The 
mail was addressed to the person responsible for ESBL testing in hospitals. Before placing the 
questionnaire in email short introduction about the project was mentioned. The questionnaire 
is attached as appendix 1. 
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2.5 Analysis methods 
Data analysis is a process of inspecting, cleansing, transforming and modelling data in order 
to have useful information, informing conclusions and supporting decision making process 
(Selene Xia & Gong, 2014). The main analysis activity was expected to be construction of 
price elasticity profile and calculation of confidence intervals. Unfortunately, it is clear that 
data are too limited for any such analysis. Instead, analysis will just be based on comparison 
of what can be estimated as realistic sales price compared to what the responding hospitals are 
willing to pay.  
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3. Results 
The results in this thesis can be grouped in three. First there is the information obtained by 
interviewing one of the foremost Norwegian experts on ESBL testing, professor Rafi Ahmad. 
Second, there is the results from the survey described under Materials and Methods. Finally 
some results are calculations based on official statistics or data from suppliers. It important to 
stress that whereas the data obtained from literature search cannot be considered results, any 
information obtained by analysis, calculations or cross-tabulation of such data can be 
considered results. All prices referred to in this thesis is without VAT. 
3.1 Interview 
The summary of the interview done with professor Rafi Ahmad is mentioned as, at first he 
said that he is working on ESBL using sequencing technology, so he can answer anything only 
about sequencing related to ESBL. And about the kits use and its pricing, he suggested to visit 
hospitals to get further information as he is not using any kits and related technology method, 
so he cannot say anything related to kits method. 
He mentioned, to go for the detection of ESBL, certain steps have to be followed as mentioned 
below. 
First, we need to check whether the sickness is due to bacteria or virus. If its bacteria then we 
need to go for go for the culture of this bacteria from clinical sample, it may take 24 to 48 
hours or even more in some cases, then we need to look for which bacteria is this, after that 
whether the bacteria is resistant or not, then we need to check for bacterial species.  
So, for this detection method traditional culture is necessary and he don’t fully support that 
kits use method can be the better than traditional culture (Phenotypic test) technique. Also, he 
mentioned that detection of ESBL directly from the clinical sample without going through 
microbiological culture is not possible. Also, he said that even if you use kits, you have to go 
through microbiology test and the kits method do not detect new strain. So his overall saying 
was traditional detection method is the best till now. 
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3.2 Survey 
Four of the contacted hospitals gave a response, three of them by filling in the forms and the 
last one by stating that they felt that it was wrong to focus on economic alone. The responses 
are anonymized, the three hospitals referred to as hospitals A, B and C, respectively. Very few 
numbers of response have been obtained from the targeted hospitals and most of them did not 
reply the email. The hospitals that gave a meaningful response provide health coverage for 
roughly 701 000 individuals as of 2017 according to their own annual reports. That constituted 
some 13% of the Norwegian population at the time. 
The results from the survey are tabulated below. 
The first question in the survey was: Provided that PCR based ESBL detection is as sensitive 
and as precise as the traditional methods and has 24 hours shorter time to results, would you 
consider changing from the traditional methods if the price was low enough? All three 
responding hospitals answered that they would, but one hospital (C) answered that if possible 
they would prefer a fast method that would also detect new ESBL varieties. Although the 
questionnaire specifically asks for PCR based methods, it must be assumed that the answer 
will also cover LAMP based methods, as they have the same strengths and weaknesses as PCR 
based tests.     
The second question was: Which price per test would make you switch to PCR based ESBL 
detection for screening? 
 
Table 5: Price that hospitals will pay for fast molecular ESBL screening tests. 
Price per test in NOK  Hospitals 
50 A 
150 B, C 
450 - 
1000 - 
2500 - 
 
As seen from the table 5, two of the hospitals was found to be ready to pay 150 NOK and one 
hospital was interested to pay 50 NOK for PCR based ESBL detection for screening per test. 
None of the hospitals were interested to go for higher price as mentioned in the table. 
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The third question was: Which price per test would make you switch to PCR based ESBL 
detection for clinical sample? 
Table 6: Price that hospitals will pay for fast molecular ESBL tests (clinical samples). 
Price per test in NOK Hospitals 
50 A, C 
150 B 
450 - 
1000 - 
2500 - 
 
As seen from table 6, for clinical samples testing, two hospitals are found to be interested to 
pay 50 NOK and only one hospital is ready to pay 150 NOK. 
Question number 4 was: Would you prefer to have a kit that uses your current PCR 
instruments? All of the hospitals who have responded to survey are interested to go for kit 
method which uses their current PCR instrument. 
Question number 5 was: If you should buy an instrument dedicated to fast ESBL testing, what 
would you deem to be sufficient maximum number of samples per run?  
Table 7: Test capacity deemed sufficient by the different hospitals. 
Number of samples per run Hospitals 
8 A 
24 B, C 
48 - 
96 - 
>96 - 
 
From table 7 it is seen that, hospitals B and C wants 24 samples to be run at a time but hospital 
A want only 8 sample to be run in one time.  
Question number 6 was: Based on your answer to Q5, what would you consider a reasonable 
price for the instrument that can handle the analysis (PCR) part of fast ESBL testing?  
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Table 8: Price considered reasonable for an ESBL test analysis instrument.   
Price in NOK  Hospitals 
5000 - 
15 000 A 
45 000 C 
100 000 B 
300 000 - 
 
From table 8 it can be seen that there is a relatively wide range of what the hospitals are willing 
to pay for test instruments, in this case qPCR or LAMP instruments. It is also important to 
note that hospital A is the respondent that feels that the price should be lowest. It is also this 
respondent that only needs a throughput of eight samples per run. 
Question number 7 was: Based on your answer to Q5, what would you consider a reasonable 
price for the instrument that can handle nucleic acid extraction and PCR setup as well as the 
analysis (PCR) part of fast ESBL testing? 
Table 9: Price considered reasonable for an ESBL test sample prep + analysis instrument. 
Price in NOK Hospitals 
10 000 - 
30 000 C 
100 000 A 
250 000 B 
500 000 - 
 
As can be seen from table 9, hospitals A and B are willing to pay a premium for a system that 
includes sample preparation. This does not seem to be the case for hospital C. 
Question number 8 was: What would you consider an acceptable price for a kit used by the 
instrument described in question 7, including reagents for nucleic acid extraction as well as 
for analysis (PCR or similar)? 
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Table 10: Price that hospitals will pay for fast molecular ESBL tests including sample prep. 
Price per test in NOK Hospitals 
50 A, C 
150 B 
450 - 
1000 - 
2500 - 
 
From the above table it was seen that none of the hospitals were interested in paying a 
significant premium for a kit that includes sample preparation. 
3.3 Derived data 
None of the responding hospitals have published their resistance testing data in recent years. 
However, in “Resistensrapport for Sykehuset Innlandet 2018” (Sykehuset Innlandet 2018) it 
is stated that in general the incidence of antibiotic resistance at Sykehuset Innlandet is close to 
the national average. The number of performed ESBL tests from Sykehuset Innlandet are 
therefore considered representative for the number of ESBL tests needed for a population of 
the size served by Sykehuset Innlandet HF (408 051 inhabitants as of 31st December 2017; 
Sykehuset Innlandet HF Annual Report 2017). 
“Resistensrapport for Sykehuset Innlandet 2018” (Sykehuset Innlandet 2019) is an official 
report which is basically an automatic report from the database tool Crystal reports 2018, with 
an unsigned introduction. It can be found on the hospital’s website and the link is given in the 
reference list (SykehusetInnlandet, 2018).  
The relevant ESBL test data extracted from the tables of the resistance report is: 
Blood culture 
E.coli: 349 tests from 324 patients. 14 tests positive for ESBL A. 
Klebsiella pneumonia: 82 tests from 72 patients. 3 tests positive for ESBL A. 
Urine (both from hospital and outpatients) 
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E.coli: 7322 tests from 5377 patients. 165 tests positive for ESBL A + 1 positive for ESBL M. 
Klebsiella pneumonia: 2041 tests from 1697 patients. 65 positive for ESBL A + 1 positive for 
ESBL M. 
Screening 
A total of 425 patients were tested. 84 were positive. 
This adds up to 10 219 tests, or roughly 25 tests per 100 individuals that the hospital provides 
health care for. 
The hospital labs responding to the survey are all of a similar size, so it seems to be logical to 
use average numbers for estimating the number of test per laboratory per year. The labs on the 
average provide tests for 234 000 inhabitants, which means 5853 tests per year. A large 
proportion of these would be performed in connection with planned admission. To get an upper 
estimate of the PCR capacity requirement for these laboratories, the number of samples per 
year was divided by the number of working days in 2017 (251) to get 23.3 samples per day. 
This is clearly an overestimate of samples per run. Running one PCR reaction per working 
day would waste the time to result advantage that molecular testing offer. It does, however 
align well with the numbers obtained from the survey in that more than 24 samples are not 
needed.  
 
Price per test calculations for eazyplex superbug kits: 
According to the UK based National Institute for Health and Care Excellence (NICE), the cost 
of the Genie II device described in the introduction is GBP (£) 9,000. 
 
The cost of Kits: GBP 1542, which contains 48 single use test kits,  
Therefore, for single time use, we have 1542/48=32.13 
 
Also, according to the institute, unit cost for traditional microbiological culture is GBP 7.00 
So roughly if I take, 1 GBP = 11 NOK. 
 
Then, we have Unit cost by using kits is 32.13*11=353.43 NOK. 
And unit cost by using microbiological culture is 7*11=77 NOK. 
 
From the above figure though it looks, by using kits it becomes so much expensive but if we 
see the time duration of the result and efficiency in detection of the CPO and ESBLs genes, it 
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can be justifiable that using kits is better than traditional microbiological culture technique 
(NICE, 2017).  
 
Price per test calculations for ESBL PCR kit from manufacturer company Gene Proof: 
Price is from the site of the distributor Medac Diagnostica GmbH. 
We have ESBL PCR kit for 25 reactions for 490 EURO and 50 reactions for 890 EURO, 
Here, if 1 EURO= 10 NOK (Approximately) 
Then we have for 50 reactions, on 890 EURO. 
For 1 reaction 890/50 =17.8 EURO 
Therefore for 1 reaction we have, 17.8*10 = 178 NOK (MedacDiagnostics, 2016). 
While this thesis was written, the Gene Proof ESBL PCR kit was withdrawn from the market.  
 
  
 
 
 
 32
4. Discussion 
This thesis with an intention to know the price sensitivity in the clinical testing market for 
ESBL, its evaluation cannot be conclusive due to limited number of respondents. If there 
would have been more response, then better explanation could have been obtained about 
pricing of the instruments and its kits. The hospitals who do not answer the survey, may be 
because of their privacy issues or they do not want to be in public about their systems.  
In the questionnaire there seems to have some limitations, the upper limit of pricing scale of 
the kits and instruments have been set much higher, it would have been better to have more 
pricing points in the lower end of the scale. When asking for the reasonable price for analysis 
plus extraction instrument, it would have been better to ask how much they would be willing 
to pay in addition to the price of analysis instrument. The question related to extraction of 
nucleic acid and analysis of the clinical sample could have been separately mentioned. 
The prices about the kits is not possible to achieve as what the customers are expecting and it 
seems lower than the range mentioned by the diagnostic company and health care excellence. 
None of the customers go above 150 NOK, as the pricing mentioned by diagnostic company 
and health care excellence are 178 NOK and 353.43 NOK respectively (MedacDiagnostics, 
2016; NICE, 2017). Also, the kits available for MRSA detection from Medac diagnostica, its 
pricing is 187 NOK per sample, so its not possible to have ESBL detection kits in lower prices 
than as mentioned above (MedacGmbHDiagnostika, 2017). However, the next step on the 
price “ladder” of the questionnaire is 450 NOK/sample, so it is not unrealistic that the 
respondents that answered 150 NOK would be willing to prices comparable to that of Gene 
Proof kit (178 NOK/sample). On the other hand, the fact that the kit is no longer on the market 
may mean that the price was either too high to achieve sales or too low to make a profit. 
When question about whether or not they preferred kits that could utilize their existing analysis 
equipment, all the respondents answered yes. This seems to be in contrast to the results of 
Parajuli (Parajuli, 2018). One of the obstacles to using PCR based ESBL detection that 
appeared in the responses to his survey was that the existing PCR equipment was either old or 
overloaded with other tests. One possible explanation for this difference is that the hospitals 
responding to Parajuli’s survey were the largest ones in Norway, whereas the respondents to 
this survey are medium size. Another possibility is that the difference is just due to small 
sample size. 
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The respondents also were very reluctant to pay much for a pure analysis instrument. This may 
be related to the fact that they preferred to use their existing equipment. Only one of the 
respondents (B) was willing to pay what is a realistic price for a qPCR or a LAMP instruments. 
There is a range of small qPCR instruments available for less than 100 000 NOK and the 
LAMP instrument Genie II will come in at around 100 000 NOK. Another respondent might 
be able to find a small capacity qPCR instrument at a slightly higher price than they are willing 
to pay 45 000 NOK. For instance there is a dual channel 16 sample qPCR instrument available 
at 6500 USD, which is equal to 56 500 NOK approximately (Chai, 2019). There is no qPCR 
solution currently available at 15 000 NOK, which is the price range that hospital A wants. 
The only way to achieve something like this price would have to be using end-point PCR. 
Respondents A and B were more willing to pay for a combined instrument for sample prep 
and analysis. B was willing to add 150 000 NOK for the extraction part and A was willing to 
add 85 000 NOK. These are both realistic prices, but since A was unwilling to pay a realistic 
price for the analysis part, it is only respondent B that is interested in paying a realistic price 
for a combination instrument. Respondent C requires a special comment. Apparently, they 
seem to, willing to pay less for a combination instrument than for a stand-alone analysis 
instrument. This may be an artefact of the questionnaire. The hospital has answered 30 000 
NOK for the combination instrument, which is closer to the 45 000 NOK they have answered 
for the analysis instrument than the next step up the “ladder” (100 000 NOK). What this really 
mean is that respondent C is not interested in paying much of a premium for adding sample 
prep.  
When the patients are admitted in the hospitals and if ESBLs are detected from patients’ 
sample by chance then such patients are kept in isolation (Lingaas, 2016). Also, when patients 
admitted and screened by culture technique then patients are kept in isolation for 5 days till 
result of the culture comes. The duration of the positive patients which are kept in isolation 
varies depending on the techniques used for detection. If culture technique is followed then 
isolation is done for 20 days, and isolation ended when the three successive cultures comes 
negative and if PCR technique is followed then isolation is done for 7 days. Also, culture 
screening costs 7 EURO and PCR screening costs 19 EURO ( 190 NOK) but survey result 
shows only two of the customer willing to pay 150 NOK and one customer willing to pay 50 
NOK for screening by PCR, which is not achievable (Van der Zee et al., 2013).  
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The respondents all want a relatively low throughput from their dedicated analysis 
instruments, either 8 or 24. This fits with customer need calculation performed in the results 
section based on public numbers from Sykehuset Innlandet.  
Finally, there are two surprising results from the survey. One is that hospital C is willing to 
pay more for screening than for clinical samples. This seems counter-intuitive, since one 
would expect clinical samples to be more time critical. Also, none of the respondents seem to 
be willing to pay anything extra for the inclusion of sample prep in the kits. This may be due 
that the steps of the price “ladder” are too far apart. As mentioned earlier in the discussion, it 
might have been better to ask how much added value they considered sample prep to be, and 
then have a range from 5 NOK to maybe 50 or 100 NOK.   
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5. Conclusion 
This thesis had two main objects:  
1. To estimate a price where molecular tests are competitive with traditional techniques. 
2. To perform a price sensitivity analysis. 
Due to the low number of respondents it was not possible to perform a price sensitivity 
analysis, since this is a statistical procedure requiring large numbers.  
Data obtained from the performed survey gave some indication of the price that microbiology 
labs of medium sized hospitals are willing to pay for molecular testing for ESBL. At least in 
some circumstances some hospitals were willing to pay close to a realistic price for the reagent 
kits. One out of three hospitals was willing to pay realistic price for instrumentation. 
Two minor pieces of fact should also be mentioned here. First, one out of three hospitals was 
willing to pay higher prices for screening than for clinical samples. Second, the analytic 
instruments that these hospitals wanted should ideally have a quite low capacity, only 8 to 24 
samples per run. 
 36
6. References 
 
Andersen, B. M., Tollefsen, T., Seljordslia, B., Hochlin, K., Syversen, G., Jonassen, T. O., . . 
. Sandvik, L. (2010). Rapid MRSA test in exposed persons: costs and savings in 
hospitals. J Infect, 60(4), 293-299. doi:10.1016/j.jinf.2010.01.008 
Andrea Tübbicke, C. H., Nils-Olaf Hübner, Christian Wegner, Axel Kramer, Steffen Fleßa. 
(2013). Cost comparison of MRSA screening and management – a decision tree 
analysis. BMC Health Services Research, 12, 438. doi:10.1186/1472-6963-12-438 
Bellíssimo-Rodrigues, F., Gomes, A. C. F., Passos, A. D. C., Achcar, J. A., Perdoná, G. d. S. 
C., & Martinez, R. (2006). Clinical outcome and risk factors related to extended-
spectrum beta-lactamase-producing Klebsiella spp. infection among hospitalized 
patients. Mem Inst Oswaldo Cruz, 101(4), 415-421.  
Berendsen, B. J., Gerritsen, H. W., Wegh, R. S., Lameris, S., van Sebille, R., Stolker, A. A., 
& Nielen, M. W. (2013). Comprehensive analysis of ss-lactam antibiotics including 
penicillins, cephalosporins, and carbapenems in poultry muscle using liquid 
chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem, 405(24), 
7859-7874. doi:10.1007/s00216-013-6804-6 
Bradford, P. A. (2001). Extended-spectrum beta-lactamases in the 21st century: 
characterization, epidemiology, and detection of this important resistance threat. Clin 
Microbiol Rev, 14(4), 933-951, table of contents. doi:10.1128/CMR.14.4.933-
951.2001 
Bush, K., & Bradford, P. A. (2016). beta-Lactams and beta-Lactamase Inhibitors: An 
Overview. Cold Spring Harb Perspect Med, 6(8). doi:10.1101/cshperspect.a025247 
Chai. (2019). A FAST, ACCURATE, AND PORTABLE REAL-TIME PCR MACHINE. 
Retrieved from https://www.chaibio.com/openqpcr 
Codjoe, F. S., & Donkor, E. S. (2017). Carbapenem Resistance: A Review. Med Sci (Basel), 
6(1). doi:10.3390/medsci6010001 
Cooksey, R., Swenson, J., Clark, N., Gay, E., & Thornsberry, C. (1990). Patterns and 
Mechanisms of r-Lactam Resistance among Isolates of Escherichia coli from Hospitals 
in the United States. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 34(5), 
739-745.  
Dhama, K., Karthik, K., Chakraborty, S., Tiwari, R., Kapoor, S., Kumar, A., & Thomas, P. 
(2014). Loop-mediated Isothermal Amplification of DNA (LAMP) A New Diagnostic 
Tool Lights the World of Diagnosis of Animal and Human Pathogens A Review. 
Pakistan Journal of Biological Sciences, 17(2), 151-166. 
doi:10.3923/pjbs.2014.151.166 
Elstrøm, P. (2016). Isolering – hva koster det? Retrieved from 
https://wpstatic.idium.no/www.smittevernforum.no/2016/10/4.-P.-Elstr%C3%B8m.-
Hva-koster-isolering-Smittevernforum-2016.pdf 
Etebu, E., & Arikekpar, I. (2016). Antibiotics: Classification and mechanisms of action with 
emphasis on molecular perspectives. Int. J. Appl. Microbiol. Biotechnol. Res., 4, 90-
101.  
EUCAST. (2013). EUCAST guidelines for detection of resistance mechanisms and 
specific resistances of clinical and/or epidemiological importance. In E. C. o. A. 
S. Testing (Ed.), (1.0 ed.). European Society of Clinical Microbiology and Infectious 
Diseases. 
Fiona. (2016). How to Test For Price Sensitivity . Retrieved from 
http://www.undercoverstrategist.com/how-to-test-for-price-sensitivity/ 
 37 
GeneProof (Producer). (2016). GeneProof ESBL PCR Kit. Retrieved from 
http://www.geneproof.com/en/products/diagnostic-kits/microbiological-
dnadiagnostics/geneproof-esbl-pcr-kit 
Gidengil, C. A., Gay, C., Huang, S. S., Platt, R., Yokoe, D., & Lee, G. M. (2015). Cost-
effectiveness of strategies to prevent methicillin-resistant Staphylococcus aureus 
transmission and infection in an intensive care unit. Infect Control Hosp Epidemiol, 
36(1), 17-27. doi:10.1017/ice.2014.12 
Goldsack, J. C., DeRitter, C., Power, M., Spencer, A., Taylor, C. L., Kim, S. F., . . . Drees, M. 
(2014). Clinical, patient experience and cost impacts of performing active surveillance 
on known methicillin-resistant Staphylococcus aureus positive patients admitted to 
medical-surgical units. Am J Infect Control, 42(10), 1039-1043. 
doi:10.1016/j.ajic.2014.07.011 
Helsedirektoratet. (2019). The table shows the daily price from 2014 to 2019. Retrieved from 
https://helsedirektoratet.no/finansieringsordninger/utskrivningsklare-pasienter 
Hendrik, T. C., Voor In 't Holt, A. F., & Vos, M. C. (2015). Clinical and Molecular 
Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Klebsiella spp.: A 
Systematic Review and Meta-Analyses. PLoS One, 10(10), e0140754. 
doi:10.1371/journal.pone.0140754 
Hubner, C., Hubner, N. O., Hopert, K., Maletzki, S., & Flessa, S. (2014). Analysis of MRSA-
attributed costs of hospitalized patients in Germany. Eur J Clin Microbiol Infect Dis, 
33(10), 1817-1822. doi:10.1007/s10096-014-2131-x 
Jacoby, G. A., & Munoz-Price, L. S. (2005). The New b-Lactamases. The new england journal 
of medicine, 352, 380-391.  
Komatsu, Y., Kasahara, K., Inoue, T., Lee, S. T., Muratani, T., Yano, H., . . . Mikasa, K. 
(2018). Molecular epidemiology and clinical features of extended-spectrum beta-
lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan. PLoS 
One, 13(8), e0202276. doi:10.1371/journal.pone.0202276 
Li, J., Ulvin, K., Biboh, H., & Kristiansen, I. S. (2012). Cost-effectiveness of supplementing 
a broth-enriched culture test with the Xpert meticillin-resistant Staphylococcus aureus 
(MRSA) assay for screening inpatients at high risk of MRSA. J Hosp Infect, 82(4), 
227-233. doi:10.1016/j.jhin.2012.08.009 
Liakopoulos, A., Mevius, D., & Ceccarelli, D. (2016). A Review of SHV Extended-Spectrum 
beta-Lactamases: Neglected Yet Ubiquitous. Front Microbiol, 7, 1374. 
doi:10.3389/fmicb.2016.01374 
Lingaas, E. (2016). ESBL-producing and other multi resistant Gram negative Bacteria – 
screening and prevention of contagion. Procedure. 
McKinnell, J. A., Bartsch, S. M., Lee, B. Y., Huang, S. S., & Miller, L. G. (2015). Cost-benefit 
analysis from the hospital perspective of universal active screening followed by 
contact precautions for methicillin-resistant Staphylococcus aureus carriers. Infect 
Control Hosp Epidemiol, 36(1), 2-13. doi:10.1017/ice.2014.1 
MedacDiagnostics (Producer). (2016). Price on ESBL PCR kit. Retrieved from 
http://www.medacdiagnostika.de/index.php?id_lang=1&id_category=1015&controll
er=category&n=100 
MedacGmbHDiagnostika. (2017). MRSA Real-time PCR kit. Retrieved from 
http://www.medacdiagnostika.de/index.php?id_product=15422&controller=product
&id_lang=1 
NICE. (2017). eazyplex SuperBug kits for detecting carbapenemase producing organisms. 
Medtech innovation briefing. Retrieved from https://www.nice.org.uk/advice/mib94 
 38
Notomi, T., Okayama, H., Masubuchi, H., Yonekawa, T., Watanabe, K., Amino, N., & Hase, 
T. (2000). Loop-mediated isothermal amplification of DNA. Nucleic Acids Research, 
28(12).  
Parajuli, A. (2018). Non-economic market obstacles to fast testing for extended spectrum β 
lactamase(ESBL). (Master), Inland Norway University of Applied Sciences,  
Pegler, S., & Healy, B. (2007). In patients allergic to penicillin, consider second and third 
generation cephalosporins for life threatening infections. BMJ, 335(7627), 991. 
doi:10.1136/bmj.39372.829676.47 
Peker, N., Rossen, J. W. A., Deurenberg, R. H., Langereis, P. C., Raangs, E. G. C., Kluytmans, 
J. A., . . . Sinha, B. (2018). Evaluation of an Accelerated Workflow for Surveillance 
of ESBL (CTX-M)-Producing Escherichia coli Using Amplicon-Based Next-
Generation Sequencing and Automated Analysis. Microorganisms, 6(1). 
doi:10.3390/microorganisms6010006 
Pitout, J. D., Nordmann, P., Laupland, K. B., & Poirel, L. (2005). Emergence of 
Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the 
community. J Antimicrob Chemother, 56(1), 52-59. doi:10.1093/jac/dki166 
Poirel, L., Fernandez, J., & Nordmann, P. (2016). Comparison of Three Biochemical Tests for 
Rapid Detection of Extended-Spectrum-beta-Lactamase-Producing 
Enterobacteriaceae. J Clin Microbiol, 54(2), 423-427. doi:10.1128/JCM.01840-15 
Queenan, A. M., & Bush, K. (2007). Carbapenemases: the versatile beta-lactamases. Clin 
Microbiol Rev, 20(3), 440-458, table of contents. doi:10.1128/CMR.00001-07 
Rawat, D., & Nair, D. (2010). Extended-spectrum beta-lactamases in Gram Negative Bacteria. 
J Glob Infect Dis, 2(3), 263-274. doi:10.4103/0974-777X.68531 
Schoevaerdts, D., Bogaerts, P., Grimmelprez, A., Saint-Hubert, M. d., Delaere, B., Jamart, J., 
. . . Glupczynski, Y. (2011). Clinical profiles of patients colonized or infected with 
extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month 
retrospective study at a Belgian University Hospital. BMC Infectious Diseases, 11(12). 
doi:10.1186/1471-2334-11-12 
Seegene. (2019). Allplex™ Entero-DR Assay Simultaneous detection and identification of 8 
antibiotic resistance genes. Retrieved from 
http://www.seegene.com/neo/en/products/others/allplex_Entero.php# 
Selene Xia, B., & Gong, P. (2014). Review of business intelligence through data analysis. 
Benchmarking: An International Journal, 21(2), 300-311. doi:10.1108/bij-08-2012-
0050 
SykehusetInnlandet. (2018). Resistensrapport for Sykehuset Innlandet 2018. Retrieved from 
https://sykehusetinnlandet.no/seksjon/laboratorie/Documents/Resistensrapporter/Resi
stensrapport%20Sykehuset%20Innlandet%202018.pdf 
Thomson, K. S. (2001). Controversies about Extended-Spectrum and AmpC Beta-Lactamases. 
Emerging Infectious Diseases, 7(2).  
TulaneUniversity. (2016). Beta-lactam Pharmacology. 
http://tmedweb.tulane.edu/pharmwiki/doku.php/betalactam_pharm 
Van der Zee, A., Hendriks, W. D., Roorda, L., Ossewaarde, J. M., & Buitenwerf, J. (2013). 
Review of a major epidemic of methicillin-resistant Staphylococcus aureus: the costs 
of screening and consequences of outbreak management. Am J Infect Control, 41(3), 
204-209. doi:10.1016/j.ajic.2012.02.033 
Vásquez-Jaramillo, L., Ramírez, N. F., Akineden, Ö., & Fernández-Silva, J. A. (2017). 
Presence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae 
in bulk-tank milk of bovine dairy farms in Antioquia, Colombia. Rev Colomb Cienc 
Pecu, 30, 85-100. doi:10.17533/udea.rccp.v30n2a01 
 39 
Wintermans, B. B., Reuland, E. A., Wintermans, R. G., Bergmans, A. M., & Kluytmans, J. A. 
(2013). The cost-effectiveness of ESBL detection: towards molecular detection 
methods? Clin Microbiol Infect, 19(7), 662-665. doi:10.1111/j.1469-
0691.2012.03998.x 
 40
Appendix 1-Survey Questions 
The answers to the questions below will contribute to the master thesis “Price sensitivity in 
the market for Extended-Spectrum ß-Lactamase (ESBL) testing”  
 
Question 1: Provided that PCR based ESBL detection is as sensitive and as precise as the 
traditional methods and has 24 hours shorter time to results, would you consider changing 
from the traditional methods if the price was low enough? 
  Yes     No   
 
If yes, continue with Question 2, if no, please specify why. 
 
 
Note: all prices mentioned below is in Norwegian kroner. 
Question 2: Which price per test would make you switch to PCR based ESBL detection for 
screening? 
  50   150   450   1000   2500  
 
Question 3: Which price per test would make you switch to PCR based ESBL detection for 
clinical samples? 
  50   150   450   1000   2500  
 
Question 4: Would you prefer to have a kit that uses you current PCR instruments. 
  Yes     No 
   
Question 5: If you should buy an instrument dedicated to fast ESBL testing, what would you 
deem to be sufficient maximum number of samples per run. 
  8   24   48    96   >96   
 
Question 6: Based on your answer to Q5, what would you consider a reasonable price for the 
instrument that can handle the analysis (PCR) part of fast ESBL testing 
  5000   15 000   45 000   100 000   300 000  
 
Question 7: Based on your answer to Q5, what would you consider a reasonable price for the 
instrument that can handle nucleic acid extraction and PCR setup as well as the analysis (PCR) 
part of fast ESBL testing 
  10 000   30 000   100 000   250 000   500 000  
 
Question 8: What would you consider an acceptable price for a kit used by the instrument 
described in question 7, including reagents for nucleic acid extraction as well as for analysis 
(PCR or similar). 
  50   150   450   1000   2500  
 
